Glaxo, set back by diabetes drug, sticks to forecast

Article Abstract:

Second-quarter net profit for British pharmaceutical company GlaxoSmithKline PLC rose by 1.4% to reach 1.33 bil pounds sterling, lifted in part from a lower tax rate. Sales, however, dropped by 2.4% to 5.67 bil. The firm is holding to its full-year outlook despite concerns about side effects involving Avandia, its diabetes drug.

---

Sanofi obesity drug helps sugar levels of diabetics in study

Article Abstract:

Acomplia, an anti-obesity drug being tested by French pharmaceutical company Sanofi-Aventis S.A., is proving beneficial to diabetics. P atients taking the drug showed improved blood-sugar levels and weight loss .

Product development, Health aspects, France, Diabetics, Drug therapy, Weight reducing preparations, Anti-obesity agents, Acomplia (Medication), SNY, Sanofi-Aventis S.A.

---

Despite flat quarter, Glaxo reaffirms '07 growth forecast

Article Abstract:

First-quarter net profit for GlaxoSmithKline PLC rose only slightly to $3.02 bil, with sales declining by 4%. However, prescription drug and vaccine sales are up, supporting expectations of a successful 2007.

Forecasts, trends, outlooks, Company business forecast/projection, Company forecasts

Similar abstracts:

• Abstracts: Glaxo plans to trim jobs as profit falls. Glaxo expects earnings to fall in 2008
• Abstracts: Alcatel stakes turnaround on more cuts. Alcatel-Lucent enters new area with laptop-security product
• Abstracts: Taxing incentives: how to reduce taxable benefits when doling out rewards and perks
• Abstracts: The web to go. In pursuit of Purple Cows

This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.